WATCH LIVE: FDA advisory panel considers use of peptides
FDA / PCAC — official records & coverage — WATCH LIVE: FDA advisory panel considers use of peptides
Channel: PBS NewsHour · Our label: Government proceedings and coverage of them · Source: youtube.com/watch?v=Hat15_exKgY
What this video covers
In conclusion, I just wanted to note again that we’re glad to have you here today to participate in the Pharmacy Compounding Advisory Committee. We value your input and expertise, both of which are critical to the success of this process. We look forward to a productive meeting and to continuing to work together. And with that, I will be turning it over to my colleague, Russell Westyke.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Thus, allowing these products to be compounded would expose consumers to unproven products and displace existing safe, effective, and proven FDA-approved products, creating a real risk of clinical harm.
- Any company that aspires to prove the safety and effectiveness of a peptide will turn away from them, knowing that compounders will simply be able to sell them without ever needing to generate safety and effectiveness evidence.
- Listing BPC-157 would confuse patients and mislead them into thinking the FDA has fully endorsed BPC-157 despite major evidence gaps, especially compared to other 503A boxless substances and FDA-approved options.
- Additionally, listing BPC-157 would undermine the integrity of the FDA drug approval framework as presented by the previous individual and would create a wide bypass for FDA clinical trials and approved requirements.
- At the time of this evaluation, the nominators did not submit and FDA did not identify clinical studies in humans assessing pharmacokinetics, nonclinical pharmacokinetics, or toxicokinetic studies of KPV.
- For non-clinical safety, at the time of this evaluation, the nominator did not submit and FDA did not identify non-clinical toxicity studies to inform safety considerations for potential clinical uses of TB500.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.